Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy
January 29–February 02, 2023 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Francesco M. Marincola, Lisa H. Butterfield, David F. Stroncek and Marcela V. Maus
In Person
On Demand
January 29–February 02, 2023 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Francesco M. Marincola, Lisa H. Butterfield, David F. Stroncek and Marcela V. Maus
Available Formats:
Supported by the Directors' Fund
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandBooking Function
Fundraising
Merchandise Options
Registration Options
Sunday, January 29, 2023
Arrival and Registration
4:00–8:00 PM
Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
Van Horne Foyer
Monday, January 30, 2023
Breakfast
7:00–8:00 AM
Van Horne B/C
Welcome and Keynote Address
8:00–9:00 AM
Van Horne A
* Marcela V. Maus, Harvard Medical School
Session Chair
Session Chair
Crystal L. Mackall, Stanford University
CAR T Cells for Solid Tumors
CAR T Cells for Solid Tumors
Successes and Challenges of Cancer Immunotherapies in the Clinic
9:00–11:30 AM
Van Horne A
* Marcela V. Maus, Harvard Medical School
Session Chair
Session Chair
Nirali N. Shah, NCI, National Institutes of Health
CAR T Cells
CAR T Cells
Rayne H. Rouce, Baylor College of Medicine
Native T Cells for ACT
Native T Cells for ACT
Marcela V. Maus, Harvard Medical School
Novel CAR T Targets
Novel CAR T Targets
Aude G. Chapuis, Fred Hutchinson Cancer Research Center
T-Cell Therapy using Engineered TCRs
T-Cell Therapy using Engineered TCRs
Coffee Break
9:30–9:50 AM
Van Horne Foyer
Poster Setup
11:30–1:00 PM
Van Horne B/C
On Own for Lunch
11:30–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne B/C
Workshop 1: Manufacturing Cell Therapies
2:30–4:30 PM
Van Horne A
* David F. Stroncek, National Institutes of Health
Session Chair
Session Chair
Michael Traxlmayr, University of Natural Resources and Life Sciences, CD Laboratory for Next Generation CAR T Cells
Enhancing Tumor Specificity of EGFR-targeting Therapies
Enhancing Tumor Specificity of EGFR-targeting Therapies
Ely Porter, RootPath
Fully Synthetic TIL Enriched for Tumor Reactivity by Computational Prediction and High-Throughput TCR Synthesis
Fully Synthetic TIL Enriched for Tumor Reactivity by Computational Prediction and High-Throughput TCR Synthesis
Nickolas Serniuck, McMaster University
Generating a Universal T-Cell Therapy Using Covalent Immune Recruiters
Generating a Universal T-Cell Therapy Using Covalent Immune Recruiters
Lukas Egli, University of Zurich
Head-to-head Comparison of CD19 Directed Human CAR T and CAR NK Cells across CD28 and 4-1BB CAR Constructs
Head-to-head Comparison of CD19 Directed Human CAR T and CAR NK Cells across CD28 and 4-1BB CAR Constructs
Andrew Frisch, University of Pittsburgh
Improving Persistence and Efficacy of Cellular Therapies for Cancer through Glycolytic Reprogramming
Improving Persistence and Efficacy of Cellular Therapies for Cancer through Glycolytic Reprogramming
John B. Haanen, Netherlands Cancer Institute
In Depth Analyses of TIL Infusion Products and Correlations with Outcome of the Randomised Controlled Phase 3 Trial Comparing TIL to Anti-CTLA-4 in Advanced Melanoma
In Depth Analyses of TIL Infusion Products and Correlations with Outcome of the Randomised Controlled Phase 3 Trial Comparing TIL to Anti-CTLA-4 in Advanced Melanoma
Coffee Available
4:30–5:00 PM
Van Horne Foyer
T-Cell Factors Affecting the Potency of Cancer Immunotherapies
5:00–7:00 PM
Van Horne A
* Marco Davila, Roswell Park Comprehensive Cancer Center
Session Chair
Session Chair
* Marco Davila, Roswell Park Comprehensive Cancer Center
Mechanisms of Resistance to CAR T Cells in Hematologic Malignancies
Mechanisms of Resistance to CAR T Cells in Hematologic Malignancies
Dalia Haydar, Children's National Hospital
Evaluating the Impact of CAR Design on the Tumor Immune Microenvironment and Anti-tumor Response in Syngeneic Glioma Model
Evaluating the Impact of CAR Design on the Tumor Immune Microenvironment and Anti-tumor Response in Syngeneic Glioma Model
Zachary Steinhart, Gladstone-UCSF Institute of Genomic Immunology
Genome-wide CRISPR Activation and Interference Screens Discover Key Drivers of Primary Human T Cell Function
Genome-wide CRISPR Activation and Interference Screens Discover Key Drivers of Primary Human T Cell Function
Social Hour with Lite Bites
7:00–8:00 PM
Van Horne B/C
Poster Session 1
7:30–10:00 PM
Van Horne B/C
Tuesday, January 31, 2023
Breakfast
7:00–8:00 AM
Van Horne B/C
Conditional Reprogramming of CAR T-Cells
8:00–11:00 AM
Van Horne A
* Lei (Stanley) Qi, Stanford University
Session Chair
Session Chair
Francesco M. Marincola, Kite Pharma
Synthetic Biology Approaches to Increase Specificity and Versatility
Synthetic Biology Approaches to Increase Specificity and Versatility
Daniel J. Powell †, University of Pennsylvania
Inducible Programming of CAR T cell Function and Intrinsic Properties for Cancer Immunotherapy
Inducible Programming of CAR T cell Function and Intrinsic Properties for Cancer Immunotherapy
Robbie G. Majzner, Stanford University School of Medicine
Coopting T Cell Signaling Networks for Enhanced CAR T Cell Specificity and Efficacy
Coopting T Cell Signaling Networks for Enhanced CAR T Cell Specificity and Efficacy
Leo Scheller, École Polytechnique Fédérale de Lausanne
Short Talk: Short Talk: Controlling T-cell Signaling with Engineered Caffeine-induced Nanobodies
Short Talk: Short Talk: Controlling T-cell Signaling with Engineered Caffeine-induced Nanobodies
Paul-Joseph P. Aspuria, Synthekine
Short Talk: Short Talk: Engineered Human IL-2/IL-2Rb Orthogonal Pairs Selectively Enhance Anti-GPC3 CAR T Cells to Drive Complete Responses in Solid Epithelial Tumor Models
Short Talk: Short Talk: Engineered Human IL-2/IL-2Rb Orthogonal Pairs Selectively Enhance Anti-GPC3 CAR T Cells to Drive Complete Responses in Solid Epithelial Tumor Models
Satoru Aoyama, Tokyo Medical and Dental University
Short Talk: Short Talk: Novel Protease-mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances the Directionality of CAR-T cell Activity and Improves Target Cell Specificity
Short Talk: Short Talk: Novel Protease-mediated Double Antigen Recognizing Chimeric Antigen Receptor (CAR) Enhances the Directionality of CAR-T cell Activity and Improves Target Cell Specificity
Yama A Abassi, Agilent
Short Talk: Short Talk: Real-Time Assessment of Engineered Immune Cell Potency, Persistence and Migration from Discovery to Process Development and Manufacturing
Short Talk: Short Talk: Real-Time Assessment of Engineered Immune Cell Potency, Persistence and Migration from Discovery to Process Development and Manufacturing
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Van Horne B/C
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne B/C
Workshop 2: Equipment and Regents for Cell Therapy Problem Solving
2:30–4:30 PM
Van Horne A
* David F. Stroncek, National Institutes of Health
Session Chair
Session Chair
Juliane Mietz, University of Zurich
A Novel Autologous Tumor Model for the Study of Cellular Immunotherapy using Humanized Mice
A Novel Autologous Tumor Model for the Study of Cellular Immunotherapy using Humanized Mice
Brendan Galvin, Arsenal Biosciences
CRISPR/Cas9-based Integration of a Large and Modular Cassette into a Safe Harbor Site to Improve CAR T Cell Therapy Efficacy and Safety
CRISPR/Cas9-based Integration of a Large and Modular Cassette into a Safe Harbor Site to Improve CAR T Cell Therapy Efficacy and Safety
Samir Patel, Nexcelom from Perkin Elmer
High-throughput Method to Analyze the Cytotoxicity of CAR T Cells in a 3D Tumor Spheroid Model using Image Cytometry
High-throughput Method to Analyze the Cytotoxicity of CAR T Cells in a 3D Tumor Spheroid Model using Image Cytometry
Garrett R. Rettig, Integrated DNA Technologies
Large Knock-in in Primary T Cells with Optimized Cas9 HDR Methods and Design
Large Knock-in in Primary T Cells with Optimized Cas9 HDR Methods and Design
Jasdeep Mann, Notch Therapeutics Inc
MAD7-based Gene Editing Platform for Rapid and Efficient iPSC Engineering
MAD7-based Gene Editing Platform for Rapid and Efficient iPSC Engineering
Reka Geczy, Precision NanoSystems
Multi-Step Engineering of Gene-Edited CAR T Cells Using a Novel RNA Lipid Nanoparticle Reagent
Multi-Step Engineering of Gene-Edited CAR T Cells Using a Novel RNA Lipid Nanoparticle Reagent
Lucas E. B. de Souza, University of Sao Paulo
Optimized Virus-free Manufacturing of Allogeneic CAR T Cells via CAR Targeting to the TRAC Locus using CRISPR/Cas9
Optimized Virus-free Manufacturing of Allogeneic CAR T Cells via CAR Targeting to the TRAC Locus using CRISPR/Cas9
Robin Loesch, Horizon Discovery Ltd. Perkin Elmer Group
Pin-pointTM Technology: A Versatile Base Editing Solution for the Generation of Cell Therapies
Pin-pointTM Technology: A Versatile Base Editing Solution for the Generation of Cell Therapies
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Improving Expansion and Persistence Adoptive T-Cell Therapies
5:00–7:00 PM
Van Horne A
* Justin Eyquem, University of California, San Francisco
Session Chair
Session Chair
Justin Eyquem, University of California, San Francisco
Modification of CAR Signaling Domain
Modification of CAR Signaling Domain
Sine Reker Hadrup, Technical University of Denmark
Tracking and Characterizing Antigen-Specific T cells in Cancer Immunotherapy
Tracking and Characterizing Antigen-Specific T cells in Cancer Immunotherapy
Yvonne Y. Chen, University of California, Los Angeles
Engineering Next-Generation CAR-T Cell Therapy for Cancer
Engineering Next-Generation CAR-T Cell Therapy for Cancer
Nayan Jain, Memorial Sloan Kettering Cancer Center
Short Talk: Short Talk: Disruption of H3K9me3-mediated Gene Silencing Improves CAR T Cell Function
Short Talk: Short Talk: Disruption of H3K9me3-mediated Gene Silencing Improves CAR T Cell Function
Gengwen Tian, Baylor College of Medicine
Short Talk: Short Talk: Harnessing CRISPR/Cas9 Mutagenesis Screening for Rational Design of Next-generation CAR-NKT Therapy against Neuroblastoma
Short Talk: Short Talk: Harnessing CRISPR/Cas9 Mutagenesis Screening for Rational Design of Next-generation CAR-NKT Therapy against Neuroblastoma
Social Hour with Lite Bites
7:00–8:00 PM
Van Horne B/C
Poster Session 2
7:30–10:00 PM
Van Horne B/C
Wednesday, February 1, 2023
Breakfast
7:00–8:00 AM
Van Horne B/C
Cell Trafficking and Modulating the Tumor Microenvironment
8:00–11:00 AM
Van Horne A
* Stephen Gottschalk, St. Jude Children's Research Hospital
Session Chair
Session Chair
Caetano Reis e Sousa, Francis Crick Institute
Dead Cell Recognition in Immunity to Cancer
Dead Cell Recognition in Immunity to Cancer
Andreas Lundqvist, Karolinska Institutet
Regulation of NK Cell Activity is Solid Tumors
Regulation of NK Cell Activity is Solid Tumors
Stephen Gottschalk, St. Jude Children's Research Hospital
Two Cell Therapy Vignettes: Synapse Tuning and Targeting the ECM
Two Cell Therapy Vignettes: Synapse Tuning and Targeting the ECM
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center
Targeting Solid Malignancies With Patient-Derived ‘Public' Neoantigen TCRs
Targeting Solid Malignancies With Patient-Derived ‘Public' Neoantigen TCRs
Stephen P. Schoenberger, La Jolla Institute for Immunology
Evaluating the Therapeutic Potential of Natural Neoantigen-specific CD4+ T Cells
Evaluating the Therapeutic Potential of Natural Neoantigen-specific CD4+ T Cells
Coffee Break
9:00–9:20 AM
Van Horne Foyer
Poster Setup
11:00–1:00 PM
Van Horne B/C
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Van Horne B/C
Career Roundtable
3:00–4:30 PM
Van Horne B/C
Lei (Stanley) Qi, Stanford University
Associate Professor
Associate Professor
Erin Nevius, BMS
Senior Principal Scientist
Senior Principal Scientist
Steve Mao, Cancer Cell
Editor-in-Chief
Editor-in-Chief
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Engineering Improved T-Cells
5:00–7:00 PM
Van Horne A
* Kole T. Roybal, University of California, San Francisco
Session Chair
Session Chair
Kole T. Roybal, University of California, San Francisco
Towards the Development of Synthetic Immunity to Cancer
Towards the Development of Synthetic Immunity to Cancer
Wilson Wong, Boston University
Engineering CAR Circuits
Engineering CAR Circuits
Lei (Stanley) Qi, Stanford University
Valency-controlled Receptor for Inducible CAR T Control and Multiplexed T Cell Engineering
Valency-controlled Receptor for Inducible CAR T Control and Multiplexed T Cell Engineering
Jeroen W. van Heijst, Neogene Therapeutics
Short Talk: Short Talk: Engineering TCR-edited T Cells with Enhanced Antigen Reactivity to Target Solid Cancers Expressing the TP53 R175H Driver Mutation
Short Talk: Short Talk: Engineering TCR-edited T Cells with Enhanced Antigen Reactivity to Target Solid Cancers Expressing the TP53 R175H Driver Mutation
Greg Allen, University of California San Francisco
Short Talk: Short Talk: Synthetic Cytokine Circuits Drive Targeted Infiltration and Proliferation of T Cells in Immune Excluded Tumors
Short Talk: Short Talk: Synthetic Cytokine Circuits Drive Targeted Infiltration and Proliferation of T Cells in Immune Excluded Tumors
Social Hour with Lite Bites
7:00–8:00 PM
Van Horne B/C
Poster Session 3
7:30–10:00 PM
Van Horne B/C
Thursday, February 2, 2023
Breakfast
7:00–8:00 AM
Van Horne B/C
Novel Targets and the Role of Endogenous Antigen Presentation
8:00–11:00 AM
Van Horne A
* Lisa H. Butterfield, University of California San Francisco
Session Chair
Session Chair
Catherine J. Wu, Dana-Farber Cancer Institute
T-Cell Therapy using Neoantigen Reactive TCRs
T-Cell Therapy using Neoantigen Reactive TCRs
Lisa H. Butterfield, University of California San Francisco
Critical Aspects of DC Metabolism
Critical Aspects of DC Metabolism
Michael Klichinsky, Carisma Therapeutics
CAR Macrophages for Solid Tumor Immunotherapy
CAR Macrophages for Solid Tumor Immunotherapy
Angela Zhang, MIT
Universal Redirection of Chimeric Antigen Receptor T Cells against Solid Tumors via Tumor Cell Membrane-inserting CAR Ligands
Universal Redirection of Chimeric Antigen Receptor T Cells against Solid Tumors via Tumor Cell Membrane-inserting CAR Ligands
Katherine Audsley, Telethon Kids Institute
Short Talk: Short Talk: Identifying Novel Therapeutic Targets to Improve Adoptive Cell Therapy using a Model of Flt3L-mediated Tumor Suppression
Short Talk: Short Talk: Identifying Novel Therapeutic Targets to Improve Adoptive Cell Therapy using a Model of Flt3L-mediated Tumor Suppression
Coffee Break
9:00–9:20 AM
Van Horne Foyer
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Van Horne Foyer
Allogeneic Immunotherapies
5:00–6:45 PM
Van Horne A
* David F. Stroncek, National Institutes of Health
Session Chair
Session Chair
Barbra Sasu, Allogene Therapeutics
Engineering Allogeneic CAR T Cells to Avoid GvHD and to Prevent Immune Rejection
Engineering Allogeneic CAR T Cells to Avoid GvHD and to Prevent Immune Rejection
George Coukos, University Hospital of Lausanne - CHUV
Orthogonal Cytokine Engineering Drive Synthetic T Cell Effector States
Orthogonal Cytokine Engineering Drive Synthetic T Cell Effector States
David F. Stroncek, National Institutes of Health
Optimizing Engineered T Cell Manufacturing
Optimizing Engineered T Cell Manufacturing
Liam R Campion, Century Therapeutics
Short Talk: Short Talk: Preclinical Characterization of CNTY-101, an Allogeneic iPSC-derived NK Product Candidate for the Treatment of B Cell Malignancies
Short Talk: Short Talk: Preclinical Characterization of CNTY-101, an Allogeneic iPSC-derived NK Product Candidate for the Treatment of B Cell Malignancies
Meeting Wrap-Up and Future Directions (Organizers)
6:45–7:00 PM
Van Horne A
Social Hour with Lite Bites
7:00–8:00 PM
Van Horne B/C
Cash Bar
8:00–9:00 PM
Van Horne B/C
Friday, February 3, 2023
Departure
8:00–8:00 AM
Subscribe for Updates